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The chronic inflammatory skin diseases hidradenitis sup-
purativa (HS) and psoriasis have been linked to cardio-
vascular risk factors and the latter has also been linked 
to possible renal dysfunction. Since basement membrane 
thinning in the skin of HS patients has been described, we 
speculated whether similar basement membrane defects 
might occur in renal tissue. Our objective was to investi-
gate a possible association between HS and renal dysfun-
ction. We performed a hospital and population-based 
cross-sectional study using estimated Glomerular-Fil-
tration-Rate (eGFR) to assess renal function. Thirty-two 
hospital individuals with HS, 430 population individuals 
with HS, and 20,780 population individuals without HS 
(controls) were identified. The age-, sex-, smoking-, BMI-, 
hypertension- and diabetes-adjusted analysis revealed 
a statistically significant higher eGFR for the hospital 
group with HS and a mean difference in eGFR of 6.81 
(1.27–12.35) ml/min/1.73 m2 between the hospital group 
with HS and the population group without HS. The ob-
served higher eGFR in the hospital group with HS indi-
cates a possible association of HS and renal dysfunction. 
Key words: co-morbidities; epidemiology; estimated glo-
merular filtration rate (eGFR); hidradenitis suppurativa 
(HS); hyperfiltration; inflammation.
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During the last decade evidence that chronic inflamma-
tory skin diseases may be linked to systemic disorders 
has accumulated. For example, psoriasis has been linked 
to metabolic syndrome and cardiovascular disease, and 
recently also to renal dysfunction (1–4).
Hidradenitis suppurativa (HS) is a chronic inflamma-
tory skin disorder, which manifests itself as recurrent 
painful deep-seated boils and fistulae in apocrine gland-
bearing skin, i.e. axillae and groin with subsequent 
scarring (5, 6). A population-based prevalence of 2.1% 
has been reported (7), and an association to metabolic 
syndrome has been described (8–10). Furthermore, 
basement membrane thinning in the skin of HS patients 
has been suggested (11). It may be speculated that a 
similar defect can occur in other tissues, e.g. renal tis-
sue, where a disturbance of the glomerular basement 
membrane may promote hyperfiltration.
We therefore hypothesised that HS may be associated 
with renal dysfunction independent of traditional risk 
factors, i.e. overweight, hypertension and diabetes, and 
have therefore investigated a possible association bet-
ween HS and renal dysfunction taking advantage of the 
Danish General Suburban Population Study (GESUS), 
a cross-sectional study of the adult Danish general 
suburban population in Naestved Municipality (70 km 
south of Copenhagen) (12), and a hospital HS group 
recruited from the outpatient clinic at the Department of 
Dermatology at Roskilde Hospital in Denmark (serving 
the region of Zealand which includes Naestved).
MATERIALS AND METHODS (Appendix S11)
RESULTS
The data used from GESUS were within the period 
January 1, 2010 to October 10, 2013. A total of 32 
individuals in the hospital HS group, 430 individuals 
in the population HS group, and 20,780 individuals 
in the population non-HS group (controls) were iden-
tified. The background factors and characteristics of 
the HS group and the non-HS group showed that the 
HS groups were predominately younger, female and 
smokers (Table SI1).
Renal function assessed by estimated glomerular 
filtration rate
The unadjusted analysis revealed a statistically sig-
nificant mean difference (MD) of 17.61 ml/min/1.73 
m2 (95% CI 11.10–24.13) (p < 0.0001) for the hospital 
HS group vs. non-HS group, and a statistically signi-
ficant MD of 6.42 ml/min/1.73 m2 (95% CI 4.63–8.22) 
(p < 0.0001) for the population HS group vs. the non-
HS group (Tables SII and SIII1).
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The age-, sex- and smoke-adjusted analysis revealed 
a mean eGFR of 94.63 ml/min/1.73 m2 (95% CI 89.99–
99.27) for the hospital HS group, 88.00 ml/min/1.73 m2 
(95% CI 86.72–89.29) for the population HS group, and 
88.41 ml/min/1.73 m2 (95% CI 88.10–88.71) for the 
population non-HS group. Thus, yielding a statistically 
significant age-, sex- and smoke-adjusted MD of 6.22 
ml/min/1.73 m2 (95% CI 0.92–11.53) (p > 0.0172) for 
the hospital HS group vs. the non-HS group, and a sta-
tistically non-significant age-, sex- and smoke-adjusted 
MD of –0.40 ml/min/1.73 m2 (95% CI –1.87–1.06) 
(p = 0.7866) for the population HS group vs. the non-HS 
group (Tables SII and SIII1).
The age-, sex-, smoke-, BMI-, hypertension- and dia-
betes-adjusted analysis revealed a mean eGFR of 95.53 
ml/min/1.73 m2 (95% CI 90.66–100.40) for the hospital 
HS group, 90.25 ml/min/1.73 m2 (95% CI 88.55–91.96) 
for the population HS group, and 88.72 ml/min/1.73 m2 
(95% CI 88.10–89.34) for the population non-HS group. 
Thus, yielding a statistically significant age-, sex-, smo-
ke-, BMI-, hypertension- and diabetes-adjusted MD of 
6.81 ml/min/1.73 m2 ((95% CI 1.27–12.35) (p = 0.0119) 
for the hospital HS group vs. the non-HS group, and a 
statistically non-significant age-, sex-, smoke-, BMI-, 
hypertension- and diabetes-adjusted MD of 1.53 ml/
min/1.73 m2 (95% CI –0.35–3.41) (p = 0.1322) for the 
population HS group vs. non-HS group (Fig. 1, Tables 
SII and SIII1).
Stratifying eGFR levels according to chronic kidney 
disease (CKD) stages revealed a statistically higher 
frequency of eGFR> = 90 ml/min/1.73 m2 in HS groups 
compared to the non-HS group (Table SII1).
With regard to a possible association between HS 
severity degree and eGFR we found diverging results; 
a statistically significant association between the 3 HS 
severity degrees and eGFR; the more severe the HS 
was, the higher eGFR was (Table SIV1).
In contrast, the association between number of boils 
and eGFR was statistically non-significant (p = 0.1307). 
Similarly, the association between Sartorius score and 
eGFR was statistically non-significant (p = 0.1996).
Lastly, an age-, sex-, and smoking-adjusted subgroup 
analysis of severe population-based HS group (n = 93) 
only, revealed no difference in eGFR when compared 
to the non-HS group (p = 0.598).
DISCUSSION
The body of literature describing renal complications 
in chronic cutaneous inflammation is scarce, but renal 
dysfunction has been described in patients with psoria-
sis (4). To the best of our knowledge the association of 
HS and renal dysfunction is a hitherto unexplored topic.
We found that eGFR was higher for both the hospital 
and population-based HS groups when compared to the 
non-HS group (controls). When adjusting for background 
factors and possible confounders, the eGFR was only sig-
nificantly higher in the hospital HS group vs. the non-HS 
group. Individuals recruited from a hospital outpatient 
clinic is more likely to represent severe skin disease than 
individuals recruited from the general population. This 
is supported by the distribution of severity observed in 
this study (Table SI1). According to Hills causal criteria 
in epidemiology a possible dose-response relationship 
favours causality. The fact that the hospital HS group 
(i.e. predominantly severe HS) has a higher eGFR when 
compared to the population HS group (ie. mild–severe 
HS) may thus suggest a causal relationship between HS 
and eGFR. Supportive of this we found a direct relation-
ship between HS severity degree and eGFR. However, 
the results must be seen in light of a possible selection 
bias,  i.e. the hospital and population HS groups may also 
represent certain subgroups or subtypes of HS and the 
inclusion criteria of the two HS groups varied.
The observed higher eGFR in the hospital HS group 
remains after adjusting for potential confounders inclu-
ding elements of the metabolic syndrome, suggesting 
that the HS comorbidities may not entirely explain the 
higher eGFR.
A histology study of skin samples from 20 HS patients 
suggested a structural defect of the basement membrane 
zone in the folliculopilosebaceous unit (11). We spe-
culated that a similar defect could occur in other tissues, 
e.g. renal tissue, where a similar thinning of glomerular 
basement membrane may promote glomerular hyperfil-
tration, and subsequent augmented eGFR and proteinuria.
An association between the metabolic syndrome 
(MetS) and CKD as well as HS has been demonstrated 
Fig. 1. Age-sex-smoking-BMI-hypertension-diabetes-adjusted eGFR mean 
values (95%CI) for the hospital HS- group, population HS- group, and 
population non-HS- group. The Mean Difference between the hospital HS 
group and non-HS group was 6.81 ml/min/1.73 m2  (p = 0.0119), and the 
Mean Difference for the population HS group vs. the non-HS group was 
1.53 ml/min/1.73 m2 (p = 0.1322).
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(8–10, 15–18). MetS is a cluster of cardiovascular risk 
factors, i.e. insulin resistance/diabetes, dyslipidemia, 
hypertension, and obesity. Glomerular hypertension and 
hyperfiltration is a recognised early change in subjects 
with diabetes and hypertension (19, 20). Dyslipidemia 
seems to damage podocyte function leading to protein 
leakage (21) and accumulation of lipids in the glomerular 
capillary endothelial and mesangial cells may stimulate 
local inflammation leading to chronic nephro pathy (22, 
23). Obesity-related nephropathy appears to include an 
increased renal blood flow, augmentation of GFR, and 
proteinuria as well as vascular changes resulting from 
renal hyperfiltration and hyperperfusion (24–26).
The treatment regime of HS include systemic cy-
closporine and rifampicin, both known to be associated 
with risk of kidney injury, although the latter very rarely 
(27–29). 
Chronic inflammation may interlink atherosclerosis, 
MetS, CKD, and HS (26, 30–33). The inflammatory 
cytokine TNF-alpha, which has been linked to HS 
pathogenesis, induces mineralisation of vascular cells 
in vitro (34), appears to induce apoptosis of renal cells 
(35), and progression of diabetic nephropathy (36). 
Thus, chronic inflammation in HS may mediate renal 
vascular change and apoptosis of renal cells with sub-
sequent alterations in renal function.
No commonly acknowledged definition of glomerular 
hyperfiltration exists (37). However, several studies 
set the threshold for hyperfiltration from 125 to 175 
ml/min/1.73 m2 (37). Glomerular hyperfiltration has 
been observed as a physiological response as well as a 
pathological sign (37).
Although the traditional perception of renal dysfunc-
tion reduced renal flow and low eGFR, an increased 
GFR can be an expression of early manifestations of a 
renal dysfunction.
 Both the association of eGFR with cardiovascular risk 
and mortality appear U-shaped (38, 39), i.e. both low and 
high eGFR may be predictive of increased mortality and 
cardiovascular risk. The finding may be biased by muscle 
waisting in chronic disease/malnutrition/cachexia with 
subsequent low muscle mass, low creatinine and high 
eGFR. However, a recent study adjusting for muscle mass 
found renal hyperfiltration to be a possible novel marker 
for all-cause mortality (40). Additionally, a Hazard ratio 
for all-cause mortality of 1.29 (1.19–1.41) for patients 
with high eGFR (90–119 ml/min) and an odds ratio of 
1.49 (1.05–2.09) for carotide intima media thickness in 
high eGFR (101.2–138.6 ml/min) have been reported 
(38, 39). Animal models indicate that loss of nephrons 
induce an adaptive response with increased intraglome-
rular pressure, glomerular hypertrophy, and compensary 
glomerular hyperfiltration in the spared nephrons with 
subsequent secondary glomerulosclerosis (35).The hig-
her eGFR demonstrated in the hospital HS group may 
thus reflect the earliest signs of renal dysfunction. Our 
study may have identified early as opposed to end-stage 
HS-related kidney damage, only because the HS indivi-
duals are relatively young with a mean age of 42 years. 
In aggregate, possible association between HS and 
renal dysfunction could in theory occur via one or 
several of the following mechanisms: 1) HS-basement 
membrane nephropathy, 2) co-morbidities (i.e. MetS), 
3) treatment-associated nephrotoxicity, or 4) chronic 
inflammatory-associated nephropathy. 
The major strengths of our study are the large number 
of population HS individuals and the broad inclusion of 
both hospital- and population HS individuals reducing 
selection bias and adding a broader range of disease 
severity aiding the generalisation. The HS diagnosis 
has previously been validated yielding a sensitivity of 
90% and a specificity of 97% providing information 
on misclassification bias (7). As the self-reported ques-
tions used to identify the population HS group refer to 
symptoms (i.e. boils) rather than the actual diagnosis 
(i.e. do you suffer from HS?), possible undiagnosed HS 
subjects were included. The diagnosis of the hospital HS 
group was physician-verified, and possible confounders 
were explored.
 Potential limitations should be considered. First, it is 
crucial to recognise that as this study is cross-sectional, 
we cannot prove causality. Furthermore, the population 
is suburban, Caucasian and underrepresenting the age 
group 20–30, which may limit the generalisability. 
Additionally, background factors differered between 
the HS groups and non-HS group; however, statistical 
adjustments accordingly were made. The low participa-
tion rate of the hospital HS group reduced power, and 
may furthermore have resulted in selection bias, e.g. 
only the healthiest HS patients may have participated 
whereas the most mentally and physically burdened 
patients did not have the resources to participate in 
GESUS potentially excluding the HS patients with the 
most burdensome co-morbidities. We did not include 
information on HS medical treatment or known renal 
disease. Additionally, urine analysis for protein leakage 
was not performed. The method of estimating GFR 
should be questioned as the CKD-EPI equation (see 
Appendix S11) expresses the kidney function as a body 
surface area indexed value (ml/min/1.73 m2), which 
might underestimate eGFR in patients with extreme 
body sizes (12). As HS is associated with obesity, eGFR 
for HS subjects may be underestimated. However, we 
adjusted for BMI.We used CKD-EPI since it is the best 
validated method of estimating GFR. Furthermore, as 
the non-HS population (controls) has a relatively high 
mean age, this could indicate low muscle mass, low 
creatinine, overestimation of eGFR and subsequent 
underestimation of the difference in eGFR between the 
HS group and non-HS group. CKD-EPI is, however, 
validated up to 80 years. As with any questionnaire 
survey there is a risk of recall bias.
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In conclusion, the observed higher eGFR amongst 
the hospital-based HS subjects indicates a possible as-
sociation of HS and renal dysfunction. As this is the first 
study of its kind, it may be too speculative to suggest 
clinical implications such as routine renal screening i.e. 
eGFR and urine analysis.
Future studies are warranted to confirm or reject 
our results, preferably including a urine analysis for 
protein leakage and using a follow-up study design. 
Furthermore, experimental studies on the mechanisms 
promoting a possible renal dysfunction in HS are needed 
possibly using kidney biopsies.
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